Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus

Table 5

Adverse prognostic factors identified by multivariate analysis in patients with relapsed/refractory myeloma treated with lenalidomide and dexamethasone.

Reference	Study population	PFS/TTP	Overall survival
Reece et al., 2009 [15]	130 RRMM patients treated with Len/Dex	Del(17p13); Elevated creatinine; Prior bortezomib; Prior thalidomide	Del(17p13); Elevated creatinine; Prior bortezomib; Prior thalidomide; Age >65 yrs
Klein et al., 2011 [16]	92 RRMM patients treated with Len/Dex	Del(13q) if associated with other abnormalities	Del(17p13); Amp(1q21)
Avet-Loiseau et al., 2010 [17]	207 “heavily pretreated” RRMM patients treated with Len/Dex	Progression during thalidomide; Hemoglobin <100; Del 13q	Progression during thalidomide
Dimopoulos et al., 2010 [18]	99 RRMM patients treated with Len/Dex (𝑛=50) or Len/Dex + bortezomib	t(4;14); Del(17p13); Thalidomide resistance; Elevated LDH; Extramedullary disease	Del(13q)
			Amp(1q21)
			Del(17p13)
			Thalidomide resistance; ISS
			Bortezomib resistance
			Elevated LDH
			Extramedullary disease

PFS: progression-free survival; TTP: time to progression; RRMM: relapsed or refractory multiple myeloma; Len/Dex: lenalidomide combined with dexamethasone; LDH: lactate dehydrogenase; ISS: international staging system.